- Home
- LCLN vs AVTX Comparison
LCLN vs AVTX Comparison
Compare LCLN & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCLN | AVTX |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.7M | 710.1M |
| IPO Year | 2026 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LCLN | AVTX |
|---|---|---|
| Price | $23.67 | $6.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $27.07 | ★ $44.08 |
| AVG Volume (30 Days) | 342.2K | ★ 2.1M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | $28.20 | N/A |
| Revenue Next Year | $15.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $20.05 | $6.85 |
| 52 Week High | $27.55 | $24.27 |
Technical Indicators
Market Signals| Indicator | LCLN | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 17.33 |
| Support Level | $22.81 | N/A |
| Resistance Level | $23.75 | $20.54 |
| Average True Range (ATR) | 0.87 | 0.99 |
| MACD | 0.02 | -0.43 |
| Stochastic Oscillator | 24.10 | 5.34 |
Price Performance
Historical ComparisonAbout LCLN Lincoln International Inc. Class A Common Stock
Lincoln International Inc is an independent investment banking advisory company focused on private capital markets. The company operates its business through its two operating segments: Investment Banking Advisory and Valuations and Opinions. The Investment Banking Advisory segment offers a range of services related to mergers and acquisitions, with key areas of focus including sell-side advisory, buy-side advisory, asset sales and divestitures, restructuring, primary and secondary capital raising, and merger-related engagements. The Valuations and Opinions segment provides valuation services to investment funds and financial institutions. The majority of revenue is derived from the Investment Banking Advisory segment. Geographically, the maximum revenue is derived from the Americas.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.